Although many metabolic characteristics observed in ccRCC stem from VHL loss, new evidence indicates that loss of PBRM1, SETD2, and BAP1 can also disrupt these pathways (Figure 1). Here, SETD2 is linked to nonpapillary renal cell carcinoma.